Send to a Friend Share

FDA Panel votes 13-4 not to support Columbia Labs' (CBRX) preterm birth gel

January 20, 2012 3:40 PM EST
CBRX Hot Sheet
Overall Analyst Rating:
    SELL (= Flat)

Revenue Growth %: -69.6%
FDA Panel votes 13-4 not to support Columbia Labs' (Nasdaq: CBRX) preterm birth gel.


Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!

You May Also Be Interested In


Related Categories

FDA, Trading Halts

Add Your Comment





Follow StreetInsider.com On Twitter